-
14Mar, 2024
Leadership Team From Municipal People's Congress Inspection Office Visits Gen...
On the morning of March 12th, a delegation led by Director Yu Tielong from the City People's Congress Supervisory Office visited our company for research and guidance, where they were warmly re...
-
13Mar, 2024
Genohope Extends Invitation to the Fourth MAH Cooperation and CXO Industriali...
Introduction: Welcome to the Fourth MAH Cooperation and CXO Industrialization Development and Compliance Forum! This prestigious event, hosted by Yunzi Pharmaceutical Technology Co., Ltd. and co-or...
-
28Feb, 2024
Genohope Participates in The 15th Dhaka Pharma Exhibition in Bangladesh
"Genohope Participates in the 15th Dhaka Pharma Exhibition in Bangladesh"
-
08Feb, 2024
Genohope's Participation in The First China (Xiuyu) Health Industry Exhibition
Genohope's Participation in the First China (Xiuyu) Health Industry Exhibition
-
20Dec, 2023
Inter Partes Review (IPR) challenges On 16 March 2023, Mylan Pharmaceuticals Inc. (Mylan) filed petitions for Inter Partes Review (IPR) against Novo Nordisk's semaglutide compound patents (US Paten...
-
20Dec, 2023
Update On Abbreviated New Drug Applications With The US Food And Drug Adminis...
Novo Nordisk has received notifications from several manufacturers that they have filed Abbreviated New Drug Applications (ANDAs) for liraglutide, the active pharmaceutical molecule in Victoza®...
-
15Dec, 2023
The Performance Of The Double Heroes Of Weight Loss Drugs Has Exceeded Expect...
Novo Nordisk and Eli Lilly announced its Q3 financial results, and the GLP-1 revenues were unbeatable, and it continued to soar on the road becoming a phenomenal product. Novo Nordisk's total r...
-
15Dec, 2023
GlobalData: Eli Lilly’s Weight Loss Drug Zepbound Will Sell $4.1 Billion in T...
Weight loss drugs Weight loss drugs are drugs that have the effect of weight loss. At present, the weight loss drugs in clinical use include glucagon-like-peptide-1 (GLP-1), orlistat, lorcaserin hy...
Home /